Aegis Clinical Devices CitraFlow - Precision Citrate Access Care

For Healthcare Professionals

Elevating Vascular Access Safety with Precision Citrate Solutions

Trusted heparin-free catheter locking for dialysis and intensive care, delivered in CitraFlow 4%, 30%, and 46.7% pre-filled syringes engineered for patency, infection control, and clinical confidence.

Antimicrobial
Proven antimicrobial for reducing the rates of CLABSIs
100%
Heparin-free to avoid HIT/HITTS exposure
87%
Reduction in bacteremia vs heparin in cited evidence

100% Heparin-Free

Eliminates exposure to HIT/HITTS risk and systemic anticoagulation concerns.

Biofilm Disruption

High-concentration citrate destabilizes bacterial matrices and helps inhibit coaggregation.

Zero-Reflux Design

Precision syringes are designed to prevent reflux, clotting, and inconsistent locking volumes.

Sterile Field Ready

Terminally sterilized packaging supports immediate use in high-acuity clinical settings.

Product Portfolio

Choose the lock strategy that matches catheter risk profile and workflow

Single-shot CitraFlow syringe
Flushing and Locking

CitraFlow 4% SF

For vascular access device flushing and locking, with citrate-based anti-coagulant support for routine access maintenance.

  • Anti-coagulant
  • Reduction of biofilm
  • No bacterial growth
View product details
Locking

CitraFlow 30% SF

For vascular access device locking where anti-coagulant, biofilm reduction, and antimicrobial properties are priorities.

  • Anti-coagulant
  • Reduction of biofilm
  • Antimicrobial
View product details
Concentrated Locking

CitraFlow 46.7% SF

For vascular access device locking with a higher sodium citrate concentration in the CitraFlow prefilled syringe family.

  • Anti-coagulant
  • Reduction of biofilm
  • Antimicrobial
View product details

Clinical Evidence

Evidence-based outcomes for access safety, patency, and infection prevention

Dual-shot CitraFlow syringes

Backed by multicenter trials including the referenced Weijmer study, CitraFlow positions citrate locking as a safety-forward alternative to conventional heparin protocols.

87%

Reduction in bacteremia compared with heparin in cited trial data.

Reduced Bleeding

Meta-analysis findings in the brief cite a 52% reduction in major bleeding events after switching to citrate locks.

Superior Biofilm Control

Higher citrate concentrations are presented as more effective against sessile bacteria than lower-concentration heparin mixtures.

Manufacturing Compliance

Manufactured by MedXL under ISO 13485-certified quality systems and positioned for Australian ARTG distribution disclosure.